CLINDAMYCIN PHOSPHATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H34ClN2O8PS
Molecular Weight	504.963
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]2O

InChI

InChIKey=UFUVLHLTWXBHGZ-MGZQPHGTSA-N

InChI=1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12+,13+,14-,15+,16+,18+/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf | http://www.rxlist.com/clindamycin-phosphate-topical-solution-drug.htm

Clindamycin hydrochloride is the hydrated hydrochloride salt of clindamycin. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin. Clindamycin inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome. It has activity against Gram-positive aerobes and anaerobes as well as some Gram-negative anaerobes.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial 70S ribosome 180 Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12860123	Inhibitor 8504
Bacterial 70S ribosome 180 Target ID: CHEMBL2363135 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Serious soft tissue infections 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Curative	Approved 8583	CLEOCIN HYDROCHLORIDE Approved Use Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1970
Serious respiratory tract infections 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Curative	Approved 8583	CLEOCIN HYDROCHLORIDE Approved Use Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1970
Serious skin infections 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Curative	Approved 8583	CLEOCIN HYDROCHLORIDE Approved Use Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1970
Sepsis 74 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Curative	Approved 8583	CLEOCIN HYDROCHLORIDE Approved Use Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1970
Intra-abdominal infections 50 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Curative	Approved 8583	CLEOCIN HYDROCHLORIDE Approved Use Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1970
Infections of the female pelvis 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Curative	Approved 8583	CLEOCIN HYDROCHLORIDE Approved Use Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1970
Infections of the genital tract 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Curative	Approved 8583	CLEOCIN HYDROCHLORIDE Approved Use Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1970
Acne vulgaris 34 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf	Curative	Approved 8583	CLEOCIN T Approved Use Clindamycin Phosphate is indicated in the treatment of acne vulgaris. Launch Date 1980
Lower respiratory tract infections 52 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050441s053,050639s015lbl.pdf	Curative	Approved 8583	CLEOCIN PHOSPHATE Approved Use Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Launch Date 1972
Skin and skin structure infections 81 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdf	Curative	Approved 8583	CLEOCIN PHOSPHATE Approved Use Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Launch Date 1972
Gynecological infections 8 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdf	Curative	Approved 8583	CLEOCIN PHOSPHATE Approved Use Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Launch Date 1972
Intra-abdominal infections 50 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdf	Curative	Approved 8583	CLEOCIN PHOSPHATE Approved Use Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Launch Date 1972
Sepsis 74 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdf	Curative	Approved 8583	CLEOCIN PHOSPHATE Approved Use Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Launch Date 1972
Bone and joint infections 28 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdf	Curative	Approved 8583	CLEOCIN PHOSPHATE Approved Use Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. Launch Date 1972

C_max

Value	Dose	Co-administered	Analyte	Population
3.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		CLINDAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.92 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/050803Orig1s000ClinPharmR.pdf	0.03 g 1 times / day steady-state, topical dose: 0.03 g route of administration: Topical experiment type: STEADY-STATE co-administered:		CLINDAMYCIN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
12.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		CLINDAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
13.54 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/050803Orig1s000ClinPharmR.pdf	0.03 g 1 times / day steady-state, topical dose: 0.03 g route of administration: Topical experiment type: STEADY-STATE co-administered:		CLINDAMYCIN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		CLINDAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
5 g 7 times / day multiple, vaginal Recommended Dose: 5 g, 7 times / day Route: vaginal Route: multiple Dose: 5 g, 7 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11689755	unhealthy, 16 - 51 Health Status: unhealthy Age Group: 16 - 51 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/11689755	Disc. AE: Vaginal pain or burning... AEs leading to discontinuation/dose reduction: Vaginal pain or burning (1.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/11689755
1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Anaphylactic shock Hypersensitivity reaction (severe) Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Anaphylactic shock Hypersensitivity reaction (severe) Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Anaphylactic shock Hypersensitivity reaction (severe) Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Disc. AE: Diarrhea, Clostridium difficile, Reaction skin... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Reaction skin (severe) Toxic epidermal necrolysis (grade 3-5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf

AEs

AE	Significance	Dose	Population
Vaginal pain or burning	1.2% Disc. AE	5 g 7 times / day multiple, vaginal Recommended Dose: 5 g, 7 times / day Route: vaginal Route: multiple Dose: 5 g, 7 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11689755	unhealthy, 16 - 51 Health Status: unhealthy Age Group: 16 - 51 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/11689755
Anaphylactic shock	Disc. AE	1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Diarrhea, Clostridium difficile	Disc. AE	1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Hypersensitivity reaction	severe Disc. AE	1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Anaphylactic shock	Disc. AE	300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Diarrhea, Clostridium difficile	Disc. AE	300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Hypersensitivity reaction	severe Disc. AE	300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Anaphylactic shock	Disc. AE	300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Diarrhea, Clostridium difficile	Disc. AE	300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Hypersensitivity reaction	severe Disc. AE	300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Diarrhea, Clostridium difficile	Disc. AE	450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf
Toxic epidermal necrolysis	grade 3-5 Disc. AE	450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf
Reaction skin	severe Disc. AE	450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C19 2057 CYP2E1 1060	CYP1A2 1197 CYP2A6 626 CYP2B6 776 CYP2C8 810 CYP2C18 149 CYP2C19 1119 CYP2E1 729 CYP3A5 446 CYP4A11 137

Drug as perpetrator

Target	Modality	Activity
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 1.0	moderate [Inhibition 100 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9	no
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9	no
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9	no

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050162s098s099lbl.pdf#page=3; https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	major	likely (co-administration study) Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050162s098s099lbl.pdf#page=3; https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0
CYP3A5 446	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050162s098s099lbl.pdf#page=3; https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	minor	likely (co-administration study) Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050162s098s099lbl.pdf#page=3; https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined
CYP2A6 626	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined
CYP2B6 776	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined
CYP2C18 149	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined
CYP2C8 810	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined
CYP2E1 729	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined
CYP4A11 137	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3745	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3745
eMolecules	2749645	https://www.emolecules.com/cgi-bin/more?vid=2749645

PubMed

Title	Date	PubMed
Occurrence of metronidazole and imipenem resistance among Bacteroides fragilis group clinical isolates in Hungary.	2001	11426861
Efficacy of clindamycin vaginal ovule (3-day treatment) vs. clindamycin vaginal cream (7-day treatment) in bacterial vaginosis.	2001	11368263
Superantigen antagonist peptides.	2001	11299061
Streptococcal toxic shock syndrome revealed by a peritonitis. Case report and review of the literature.	2001	11234313
Lemierre's syndrome with spondylitis and pulmonary and gluteal abscesses associated with Mycoplasma pneumoniae pneumonia.	2001 Apr	11399017
Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs.	2001 Apr	11310518
Activation of clindamycin phosphate by human skin.	2001 Apr	11309066
Severe babesiosis in Long Island: review of 34 cases and their complications.	2001 Apr 15	11283800
Successful treatment regime for folliculitis decalvans despite uncertainty of all aetiological factors.	2001 Feb	11251594
Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.	2001 Feb	11251569
Dermatopharmacology of a new combination gel formulation for the topical treatment of acne.	2001 Feb	11236214
Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? Clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide. Introduction.	2001 Feb	11236213
Potential role for a new combination topical therapy in treating mild to moderate acne vulgaris.	2001 Feb	11236212
The development of antibiotic resistance in Propionibacterium acnes.	2001 Feb	11236211
Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris.	2001 Feb	11236210
Clostridium difficile--Associated diarrhea: A review.	2001 Feb 26	11252111
[Microbiological and immunological monitoring in polyarticular rheumatoid arthritis after total joint replacement].	2001 Feb 9	11233881
[Guidelines for antibiotic prophylaxis of bacterial endocarditis in patients undergoing dental therapy].	2001 Jan	11293977
Folliculitis decalvans.	2001 Jan	11260200
Clonal relationships among penicillin-susceptible, multiresistant serotype 6B Streptococcus pneumoniae isolates recovered in Greece and France.	2001 Jan	11245328
Emerging erythromycin resistance among group B streptococci in Korea.	2001 Jan	11245325
Antibiotic sensitivity of Propionibacterium acnes isolates from patients with acne vulgaris in a tertiary dermatological referral centre in Singapore.	2001 Jan	11242619
[Prevention of endocarditis within the scope of ENT interventions. Current recommendations].	2001 Jan	11219408
Puerperal sepsis: a disease of the past?	2001 Jan	11212990
Clostridium difficile colitis following antibiotic prophylaxis for dental procedures.	2001 Jan	11209501
The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product.	2001 Jan-Feb	11281433
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae.	2001 Jun	11455504
Infection of hamsters with epidemiologically important strains of Clostridium difficile.	2001 Jun 15	11372028
A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia.	2001 Jun 25	11427101
[Antibiotic prophylaxis in oncologic pharyngolaryngeal surgery: ceftriaxone versus clindamycin and gentamycin].	2001 Mar	11428270
Persistence of Plasmodium falciparum in the placenta after apparently effective quinidine/clindamycin therapy.	2001 Mar	11324359
[Cellulitis and necrotizing fasciitis: microbiology and pathogenesis].	2001 Mar	11319369
Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America.	2001 Mar	11318814
In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics.	2001 Mar	11318076
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998.	2001 Mar	11315521
Comparative in-vitro activity of trovafloxacin and other related drugs against isolates of streptococcus oralis.	2001 Mar	11307110
Antibiotic-resistant bacteria in pediatric chronic sinusitis.	2001 Mar	11303824
Detection and characterization of a bacteriocin, garviecin L1-5, produced by Lactococcus garvieae isolated from raw cow's milk.	2001 Mar	11298239
Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children.	2001 Mar	11282264
Tufted hair folliculitis after scalp injury.	2001 Mar	11270300
Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study.	2001 Mar	11258785
Sequential parapharyngeal abscesses.	2001 Mar	11223459
Phenotypic and genotypic characterization of macrolide-resistant group A Streptococcus strains in the province of Quebec, Canada.	2001 Mar	11222568
Molecular epidemiology and genetic linkage of macrolide and aminoglycoside resistance in Staphylococcus intermedius of canine origin.	2001 Mar 20	11230937
Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS.	2001 Mar 30	11316995
[Dermo-hypodermitis and necrotizing fasciitis].	2001 Mar 31	11345864
Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones.	2001 Spring	11310804
In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification.	2001 Spring	11310802
Design and development of intraocular polymeric implant systems for long-term controlled-release of clindamycin phosphate for toxoplasmic retinochoroiditis.	2015	25709997
Clindamycin hydrochloride and clindamycin phosphate: two drugs or one? A retrospective analysis of a spontaneous reporting system.	2017 Feb	27853825

Patents

Sample Use Guides

In Vivo Use Guide

Intravenous and Intramuscular: 600-1200 mg/day in 2,3 or 4 equal doses; for the more severe infections: 1200-2700 mg/day in 2,3 or equal doses. Doses of as much as 4800 mg daily have been given intravenously. Single intramuscular injection of greater than 600 mg not recommended. Topical: apply a thin film of solution, lotion or gel twice daily to affected area.

Route of Administration: Other

In Vitro Use Guide

The minimal inhibitory concentration (MIC) for clindamycin against Staph. Aureus is 0.5 ug/ml with 97% of strains inhibited at this level. For anaerobes, the MIC is 1.6 ug/ml.

Name

Type

Language

CLINDAMYCIN PHOSPHATE

Official Name

English

CLINDAMYCIN PHOSPHATE HYDRATE

Preferred Name

English

DUAC COMPONENT CLINDAMYCIN PHOSPHATE

Common Name

English

CLINDETS

Brand Name

English

XACIATO

Brand Name

English

ACANYA COMPONENT CLINDAMYCIN PHOSPHATE

Common Name

English

BENZACLIN COMPONENT CLINDAMYCIN PHOSPHATE

Common Name

English

CLINDA-DERM

Brand Name

English

CLINDAMYCIN PHOSPHATE [USP-RS]

Common Name

English

CLINDAC

Brand Name

English

CLINDAMYCIN PHOSPHATE [USP MONOGRAPH]

Common Name

English

CLINDAMYCIN PHOSPHATE [WHO-IP]

Common Name

English

Clindamycin phosphate [WHO-DD]

Common Name

English

CLINDESSE

Brand Name

English

L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE, METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(((1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL)AMINO)-1-THIO-, 2-(DIHYDROGEN PHOSPHATE), (2S-TRANS)-

Common Name

English

CLEOCIN PHOSPHATE

Brand Name

English

CLINDAMYCINI PHOSPHAS [WHO-IP LATIN]

Common Name

English

CLINDAMYCIN PHOSPHATE [EP MONOGRAPH]

Common Name

English

NSC-618653

Code

English

CLINDAMYCIN PHOSPHATE [MART.]

Common Name

English

CLINDAGEL

Brand Name

English

DALACIN T

Brand Name

English

U-28,508

Code

English

CLINDAMYCIN PHOSPHATE [USAN]

Common Name

English

U-28508

Code

English

CLINDAMYCIN PHOSPHATE [VANDF]

Common Name

English

ZIANA COMPONENT CLINDAMYCIN PHOSPHATE

Common Name

English

VELTIN COMPONENT CLINDAMYCIN PHOSPHATE

Brand Name

English

CLINDAMYCIN PHOSPHATE [ORANGE BOOK]

Common Name

English

CLINDAMYCIN PHOSPHATE [JAN]

Common Name

English

CLINDAMYCIN (AS PHOSPHATE)

Common Name

English

CLINDAMYCIN 2-DIHYDROGEN PHOSPHATE

Common Name

English

IDP-126 COMPONENT CLINDAMYCIN PHOSPHATE

Code

English

CABTREO COMPONENT CLINDAMYCIN PHOSPHATE

Brand Name

English

EVOCLIN

Brand Name

English

7(S)-CHLORO-7-DEOXYLINCOMYCIN 2-PHOSPHATE

Common Name

English

METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(1-METHYL-TRANS-4-PROPYL-L-2-PYRROLIDINECARBOXAMIDO)-1-THIO-L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE 2-(DIHYDROGEN PHOSPHATE)

Common Name

English

L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE, METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-((((2S,4R)-1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL)AMINO)-1-THIO-, 2-(DIHYDROGEN PHOSPHATE)

Systematic Name

English

CLINDAMYCIN PHOSPHATE SYSTEM SUITABILITY [USP-RS]

Common Name

English

CLINADAC

Brand Name

English

CLEOCIN

Brand Name

English

CLINDAMYCIN 2-PHOSPHATE

Common Name

English

CLINDAMYCIN 2-DIHYDROGEN PHOSPHATE [MI]

Common Name

English

CLINDAMYCIN PHOSPHATE HYDRATE [JAN]

Common Name

English

CLEOCIN T

Brand Name

English

U 28508

Code

English

DALACIN P

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C82922